Health

Obtained an imported drug license in China for the oral synthetic quinolone antibacterial agent, which is mainly for respiratory tract infections, such as pneumonia.

Applied for manufacturing and marketing approval in Japan for a new antibacterial agent for treatment for infectious diseases in otorhinolaryngology, such as otitis media and sinusitis.

Launched Japan’s first oral antifungal agent miconazole ORAVI^® Mucoadhesive Tablets 50 mg for oropharyngeal candidiasis treatment.

Started the phase II clinical trials of a new drug candidate that accelerates rehabilitation after strokes.

Acquired a large-scale biologics manufacturing site from a major US biopharmaceutical*¹ company, Biogen.

Significantly shortened the development period of biopharmaceuticals down to 34 weeks, the shortest in the CDMO industry.

Developed a high-performance and highly efficient fully integrated continuous production system that controls processes from cultivation to purification.

Launched new product iCell^® Microglia, an iPSC-derived neural cell type, contributing to new drug evaluation in human biology, mainly for drugs for neurological diseases, such as for Alzheimer’s diseases.

FUJIFILM Wako Bio Solutions Corporation, our new company, started new subcontract services in new drug development support and inspection.

Introduce regenerative medicine products to the market, expand their application and improve contract manufacturing for these products.

Accelerate the development of new drug pipelines.

Expand contract manufacturing for biopharmaceuticals.

Develop and disseminate cell culture medium or relevant manufacturing technologies that support advanced biomedical treatments (gene therapy, etc.).

A highly sensitive rapid tuberculosis diagnostic kit, TB-LAM was adopted for the Phase 2 investment (FY2018 to FY2020) by the Global Health Innovative Technology (GHIT) Fund, to continue its clinical trials. TB-LAM is being developed by Fujifilm with the collaborating partner FIND^*3 under continuous investments from the GHIT Fund, which aims at creating innovative therapeutic drugs, vaccines, and diagnostic drugs originating in Japan to fight against infectious diseases and poverty in the developing world.

Continued to carry out the FY2017 project in Brazil to promote medical collaboration in the use of remote diagnostic imaging technology funded by the Japan International Cooperation Agency (JICA) in FY2014 (completed in March 2019).

Convened technical workshops to provide trainings to medical staff in South Africa, Myanmar, Kirghiz, etc.

Accelerate the implementation of R&D and solutions that utilize advanced medical AI Technology through the platform of “Brain(s).”

With an aim of commercialization, additional clinical trials to be conducted for TB-LAM to further accumulate data to obtain WHO recommendation. Contribute to the SDGs Goal 3 by aligning the TB-LAM initiative with the WHO target to end the global tuberculosis epidemic by 2030.

Scale up medical checkup systems and continue providing education and trainings to help improve the medical environment in emerging countries.

Promote the CureSign service among health insurance associations and consider to adopt this service as a substitute of medical exam required for life medical insurance application.

As a part of overseas business expansion, the project has initiated in Thailand with an aim to implement the service in the country under the JETRO Experimental Project.

Developed a new and unique component, Nano-Resveratrol EX, which employs a new function of collagen that helps maintain skin firmness and resilience, and launched cosmetics with functional claims containing this component.

Introduced a new product lineup that utilizes D-UV Guard+ developed based on our recent ultraviolet research.

Created the big opportunity to try ASTALIFT, through a free sample giveaway campaign for 100,000 people.

Increase the number of trial opportunities of highly-functional and scientifically-proven anti-aging care products. (Aim at a total of 10 million people who have experienced our products by 2030.)

Increase the number of people’s SNS postings on our healthcare products, such as experience reports. (Aim at a total of 100,000 postings by 2030.)

The number of people who requested gastroendoscopies and screening for breast and gynecological cancer increased steadily. The endoscopy-specialist clinic within the company premises continually encouraged employees to take large intestine endoscopies and to utilize the clinic. The number of users in FY2018 increased to 2,206 (7% over the previous year).

Promoted breast and gynecological cancer screening by dispatching a cancer screening cars.

The group-wide physical and mental health committee conducted a factor analysis concerning sick leave in order to study the signs that could indicate potential mental illness and implement countermeasures at an early stage. The committee also analyzed departmental characteristics based on stress checks and sent feedback to those departments with high risks.

Further encourage group-wide health promotion for employees and reinforce the disclosure of the results.

Under the leadership by top management of each group company, set KPIs in five priority areas and promote healthy practices.

Reinforce countermeasures against breast cancer and large intestine cancer, cases of which have increased rapidly and occupy a large percentage of the company’s medical expenses for cancer.

Organize a group-wide e-learning program to raise health awareness.

Further enhance the ongoing online stop-smoking program and a walking event.

Expand health promotion measures suitable for each region and country, and share good practices.